GlaxoSmithKline (NYSE:GSK) issued its earnings results on Wednesday. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.03, Morningstar.com reports. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. The firm had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion.

Shares of GlaxoSmithKline (NYSE:GSK) traded up $0.92 during trading hours on Thursday, hitting $36.95. The company’s stock had a trading volume of 2,023,564 shares, compared to its average volume of 5,173,329. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The stock has a market capitalization of $91,350.00, a price-to-earnings ratio of 42.94, a PEG ratio of 2.31 and a beta of 0.98. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96.

Several brokerages have recently issued reports on GSK. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Wednesday, October 18th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, October 18th. Bank of America cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, UBS Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, January 15th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $38.57.

Several large investors have recently made changes to their positions in GSK. Field & Main Bank purchased a new position in shares of GlaxoSmithKline during the fourth quarter valued at approximately $132,000. First Dallas Securities Inc. purchased a new position in shares of GlaxoSmithKline during the fourth quarter valued at approximately $142,000. Wealthcare Advisory Partners LLC boosted its position in shares of GlaxoSmithKline by 1,982.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after buying an additional 3,351 shares during the period. Quadrant Capital Group LLC boosted its position in shares of GlaxoSmithKline by 3.5% during the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after buying an additional 148 shares during the period. Finally, Advisory Services Network LLC boosted its position in shares of GlaxoSmithKline by 24.2% during the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after buying an additional 788 shares during the period. Institutional investors and hedge funds own 9.66% of the company’s stock.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline (GSK) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS” was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/02/08/glaxosmithkline-gsk-posts-quarterly-earnings-results-beats-expectations-by-0-03-eps.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.